MOXI: Males, Antioxidants, and Infertility
Brief description of study
MOXI is a research study to examine whether antioxidants can improve abnormal semen parameters in couples with male-factor infertility. Eligible male participants will be randomized to either an antioxidant supplement or placebo for 3 months, followed by fertility treatment with ovarian stimulation and intrauterine insemination.
Detailed description of study
MOXI Phase I will involve randomization to either an antioxidant supplement or placebo. This study is blinded, such that neither the participant nor the study team will know which treatment is assigned. After 3 months of treatment (with the assigned study drug), couples will be receive up to 3 consecutive cycles of female ovarian stimulation with an oral medication (clomiphene citrate), triggered ovulation with hCG, and a single intrauterine insemination (Phase II). Couples who conceive in either Phase I or Phase II will be followed through pregnancy and delivery. Male subjects will take their assigned study drug for at least 3 and up to 6 months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Male Infertility
-
Age: Between 18 Years - 100 Years
-
Gender: Male
Updated on
09 Aug 2022.
Study ID: 821457